drugset
drugset / Trial / NCT05996744

Study of Obeldesivir in Children and Adolescents With COVID-19

NCT05996744 ↗

Phase 2/3 Terminated 3 enrolled Gilead Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19). The primary objectives are to evaluate the plasma pharmacokinetics (PK), safety and tolerability of ODV in pediatric participants with COVID-19.

Timeline

Start
2023-12-26
Primary completion
2024-02-23
Completion
2024-02-23

Outcome

Outcome not reported

Stopped: “Study was terminated by Sponsor; the decision was not due to any safety findings.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Obeldesivir Small molecule 175 mg Oral
Subject Obeldesivir Small molecule 350 mg Oral

Indications

COVID-19